Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: vaccines - Beijing Minhai Biotechnology

Next Previous
Drug Profile

Research programme: vaccines - Beijing Minhai Biotechnology

Alternative Names: DTaP-Hib-sIPV combined vaccine - Beijing Minhai Biotechnology; EV71 vaccine - Beijing Minhai Biotechnology; H1N1 influenza vaccine - Beijing Minhai Biotechnology; H7N9 influenza vaccine - Beijing Minhai Biotechnology; Herpes simplex vaccine - Beijing Minhai Biotechnology; Human papillomavirus vaccine quadrivalent - Beijing Minhai Biotechnology; Meningococcal vaccine group B - Beijing Minhai Biotechnology; MR and Varicella vaccine - Beijing Minhai Biotechnology; Mumps vaccine - Beijing Minhai Biotechnology; Rotavirus vaccine 5-valent - Beijing Minhai Biotechnology; Varicella vaccine - Beijing Minhai Biotechnology; Zoster vaccine - Beijing Minhai Biotechnology

Latest Information Update: 24 Aug 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Minhai Biotechnology
  • Class Bacterial vaccines; Mumps vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diphtheria; Enterovirus A infections; Haemophilus infections; Herpes simplex virus infections; Human papillomavirus infections; Influenza A virus H1N1 subtype; Influenza A virus H7N9 subtype; Measles; Meningococcal group B infections; Mumps; Pertussis; Poliomyelitis; Rotavirus infections; Rubella; Tetanus; Varicella zoster virus infections

Most Recent Events

  • 24 Aug 2023 Preclinical development is ongoing for Diphtheria in China
  • 24 Aug 2023 Preclinical development is ongoing for Enterovirus A infections in China
  • 24 Aug 2023 Preclinical development is ongoing for Haemophilus-infections in China

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top